牵手全球AI药物设计龙头薛定谔！先声药业(02096)依托“物理+AI”双技术，重塑创新药管线估值逻辑

智通财经07-10

智通财经APP获悉，2026年7月10日，先声药业(02096)宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。先声药业首席投资官周高波表示：“我们非常高兴与全球计算药物发现领域的领导者薛定谔公司达成战略合作。双方将深度整合薛定谔全球领先的基于物理学和人工智能的...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2650066559?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-10 10:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2650066559","market":"sh","top_or_hot":-1,"title":"牵手全球AI药物设计龙头薛定谔！先声药业(02096)依托“物理+AI”双技术，重塑创新药管线估值逻辑","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，2026年7月10日，先声药业(02096)宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。先声药业首席投资官周高波表示：“我们非常高兴与全球计算药物发现领域的领导者薛定谔公司达成战略合作。双方将深度整合薛定谔全球领先的基于物理学和人工智能的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1465714.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>牵手全球AI药物设计龙头薛定谔！先声药业(02096)依托“物理+AI”双技术，重塑创新药管线估值逻辑</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n牵手全球AI药物设计龙头薛定谔！先声药业(02096)依托“物理+AI”双技术，重塑创新药管线估值逻辑\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-10 10:42 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1465714.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，2026年7月10日，先声药业(02096)宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。先声药业首席投资官周高波表示：“我们非常高兴与全球计算药物发现领域的领导者薛定谔公司达成战略合作。双方将深度整合薛定谔全球领先的基于物理学和人工智能的...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1465714.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1465714.html","article_id":"2650066559","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650066559","pubTimestamp":1783651368,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，2026年7月10日，先声药业宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。薛定谔公司将凭借其领先的物理学驱动计算平台与专业优势，负责联合药物发现阶段的计算机辅助药物设计与优化。联合药物发现阶段完成后，先声药业将主导后续临床前研究及临床开发。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159992":"创新药","BK1161":"生物科技","MEDX":"HORIZON KINETICS MEDICAL ETF","AIPO":"Defiance AI and Power Infrastructure ETF","VTHR":"Vanguard Russell 3000 ETF","06978":"永泰生物-B","BK1191":"制药","ARTY":"ISHARES FUTURE AI & TECH ETF","BK1574":"生物医药B类股","CHAT":"ROUNDHILL GENERATIVE AI & TECHNOLOGY ETF","BK1583":"高瓴概念","IBBQ":"Invesco Nasdaq Biotechnology ETF","AGIX":"通用人工智能 ETF-AGIX","02096":"先声药业","QTOC":"Innovator Growth Accelerated Plus ETF - October"},"translate_title":"Holding hands with Schrödinger, the global AI drug design leader! Simcere Pharmaceuticals (02096) relies on \"physics + AI\" dual technology to reshape the valuation logic of innovative drug pipelines","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159992":1.5,"02096":1.5,"ARTY":1.5,"AIPO":1.5,"CHAT":1.5,"VTHR":1.5,"IBBQ":1.5,"AGIX":1.5,"06978":1.5,"QTOC":1.5,"MEDX":1.5},"content_text":"智通财经APP获悉，2026年7月10日，先声药业(02096)宣布，已于近日与美国薛定谔公司达成全球药物发现与开发合作协议。双方将充分发挥各自在药物研发领域的优势，聚焦未满足的临床需求，依托先声药业在相关治疗领域的专业积累，共同推进创新药物研发。先声药业首席投资官周高波表示：“我们非常高兴与全球计算药物发现领域的领导者薛定谔公司达成战略合作。双方将深度整合薛定谔全球领先的基于物理学和人工智能的药物设计专长，以及先声药业高效的研发能力和商业化平台。我们期待通过优势互补与协同创新，加速前沿疗法的发现、开发和商业化，为全球患者提供更多突破性的治疗方案。”薛定谔公司总裁、治疗研发负责人兼首席战略合作官 Karen Akinsanya表示：“我们很高兴与先声药业开启这项战略合作，以共同研发能满足重大临床需求的创新药物。此次合作延续了我们在高价值靶点上发现创新临床候选药物的成功模式。通过将我们在‘预测优先’差异化药物设计方面的领先优势，与先声药业在中国创新研发和临床开发执行方面的卓越能力相结合，我们期待加速创新疗法的研发进程，为全球患者带来更多治疗选择。”薛定谔公司将凭借其领先的物理学驱动计算平台与专业优势，负责联合药物发现阶段的计算机辅助药物设计与优化。联合药物发现阶段完成后，先声药业将主导后续临床前研究及临床开发。根据协议，薛定谔公司有权获得合作项目在发现、开发及商业化阶段的里程碑付款，以及基于产品净销售额的阶梯式特许权使用费。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650066559","isCrawlerRequest":true}